Erratum: Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: A 3-year follow-up study (Journal of Bone and Mineral Metabolism (2004) 22 (462-468) DOI: 10.1007/s00774-004-0508-0);Alendronate reduced vertebral fracture risk in postmenopausal Japanese women with osteoporosis: A 3-year follow-up study

Journal of Bone and Mineral Metabolism

Volumn 22, Issue 5, 2004, Pages 462-468

  Kushida, Kazuhiro ^a   Shiraki, Masataka ^b   Nakamura, Toshitaka ^c   Kishimoto, Hideaki ^d   Morii, Hirotoshi ^e   Yamamoto, Kichizo ^f   Kaneda, Kiyoshi ^g   Fukunaga, Masao ^h   Inoue, Tetsuro ⁱ   Nakashima, Mitsuyoshi ^j   Orimo, Hajime ^k  

^a HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b Res Inst Pract Involutional Dis   (Japan)

^c UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^d SAN IN ROSAI HOSPITAL   (Japan)

^e Japan Osteoporosis Society   (Japan)

^f Hakuai Hospital   (Japan)

^g Bibai Rosai Hospital   (Japan)

^h KAWASAKI MEDICAL SCHOOL   (Japan)

ⁱ Aoyama General Hospital   (Japan)

^j Hamamatsu Inst of Clin Pharmacol   (Japan)

^k Tokyo Metropolitan Institute of Gerontology   (Japan)

more..

Author keywords

Alendronate; Alfacalcidol; Osteoporosis; Vertebral fracture

Indexed keywords

ALENDRONIC ACID; ALFACALCIDOL;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DUAL ENERGY X RAY ABSORPTIOMETRY; ETHNIC GROUP; FEMALE; FOLLOW UP; GASTRITIS; GASTROINTESTINAL SYMPTOM; HUMAN; INCIDENCE; LUMBAR SPINE; MAJOR CLINICAL STUDY; MEASUREMENT; MORPHOMETRICS; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; STOMACH DISEASE; VERTEBRA FRACTURE;

EID: 4544226964     PISSN: 09148779     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00774-005-0560-4     Document Type: Erratum

References (34)

1. Orimo H, Hashimoto T, Sakata K, Yoshimura N, Suzuki T, Hosoi T (2000) Trends in the incidence of hip fracture in Japan, 1987-1997: the third nationwide survey. J Bone Miner Metab 18:126-131
2. Fujiwara S, Kasagi F, Kodama K (1997) Life time risk of osteoporosis-related bone fractures in a Japanese cohort. Osteoporosis Int 7 (suppl 2):16
3. Sato M, Grasser W, Endo N, Akins R, Simmons H, Thompson DD, Golub E, Rodan GA (1991) Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest 88:2095-2105
4. Azuma Y, Sato H, Oue Y, Okabe K, Ohta T, Tsuchimoto M, Kiyoki M (1995) Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone (NY) 16:235-245
5. Liberman UA, Weiss SR, Broll J, Minne HW, Quan H, Bell NH, Rodriguez-Portales J, Downs RW Jr, Dequeker J, Favus M, Seeman E, Recker RR, Capizzi T, Santora AC II, Lombardi A, Shah RV, Hirsch LJ, Karpf DB (1995) Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. N Engl J Med 333:1437-1443
6. Tucci JR, Tonino RP, Emkey RD, Peverly CA, Kher U, Santora AC II (1996) Effect of three years of oral alendronate treatment in postmenopausal women with osteoporosis. Am J Med 101:488-501
7. Devogelaer JP, Broll H, Correa-Rotter R, Cumming DC, Nagant de Deuxchaisnes C, et al. (1996) Oral alendronate induces progressive increases in bone mass of the spine, hip, and total body over 3 years in postmenopausal women with osteoporosis. Bone (NY) 18:141-150
8. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535-1541
9. Karpf DB, Shapiro DR, Seeman E, Ensrud KE, Johnston CC Jr, Adami S, Harris ST, Santora AC II, Hirsch LJ, Oppenheimer L, Thompson D (1997) Prevention of nonvertebral fractures by alendronate. A meta-analysis. JAMA 277:1159-1164
10. Cummings SR, Black DM, Thompson DE, Applegate WB, Barrett-Connor E, Musliner TA, Palermo L, Prineas R, Rubin SM, Scott JC, Vogt T, Wallace R, Yates AJ, LaCroix AZ (1998) Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the fracture intervention trial. JAMA 280:2077-2082
11. Sharpe M, Noble S, Spencer CM (2001) Alendronate: an update of its use in osteoporosis. Drugs 61:999-1039
12. Cranney A, Wells G, Willan A, Griffith L, Zytaruk N, Robinson V, Black D, Adachi J, Shea B, Tugwell P, Guyatt G (2002) II. Meta-analysis of alendronate for the treatment of postmenopausal women. Endocr Rev 23:508-516
13. Tonino RP, Meunier PJ, Emkey R, Rodriguez-Portales JA, Menkes CJ, Wasnich RD, Bone HG, Santora AC, Wu M, Desai R, Ross PD (2000) Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group. J Clin Endocrinol Metab 85:3109-3115
14. Emkey R, Reid I, Mulloy AL, Correa-Rotter R, Favus M, Bone H, Gupta J, LaMotta A, Santora AC (2002) Ten-year efficacy and safety of alendronate in the treatment of osteoporosis in postmenopausal women. J Bone Miner Res 17 (suppl 1): S139
15. Kushida K, Shiraki M, Nakamura T, Kishimoto H, Morii H, Yamamoto K, Kaneda K, Fukunaga M, Inoue T, Nakashima M, Orimo H (2002) The efficacy of alendronate in reducing the risk for vertebral fracture in Japanese patients with osteoporosis: a randomized, double-blind, active-controlled, double-dummy trial. Curr Ther Res 63:606-620
16. Russell RGG, Rogers MJ (1999) Bisphosphonates: from the laboratory to the clinic and back again. Bone (NY) 25:97-106
17. Shipman CM, Rogers MJ, Vanderkerken K, Camp BV, Graham R, Russell G, Croucher PI (2000) Bisphosphonates: mechanisms of action in multiple myeloma. Acta Oncol 39:829-835
18. Bergstrom JD, Bostedor RG, Masarachia PJ, Reszka AA, Rodan G (2000) Alendronate is a specific, nanomolar inhibitor of farnesyl diphosphate synthase. Arch Biochem Biophys 373:231-241
19. Fleisch H (1991) Bisphosphonates: pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease. Drugs 42:919-944
20. Garnero P, Shih WJ, Gineyts E, Karpf DB, Delmas PD (1994) Comparison of new biochemical markers of bone turnover in late postmenopausal osteoporotic women in response to alendronate treatment. J Clin Endocrinol Metab 79:1693-1700
21. Guy JA, Shea M, Peter CP, Morrissey R, Hayes WC (1993) Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif Tissue Int 53:283-288
22. Balena R, Toolan BC, Shea M, Markatos A, Myers ER, Lee SC, Opas EE, Seedor JG, Klein H, Frankenfield D, Quartuccio H, Fioravanti C, Clair J, Brown E, Hayes WC, Rodan GA (1993) The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest 92:2577-2586
23. Chavassieux PM, Arlot ME, Reda C, Wei L, Yates AJ, Meunier PJ (1997) Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodeling in patients with osteoporosis. J Clin Invest 100:1475-1480
24. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone (NY) 27:687-694
25. Boivin G, Meunier PJ (2001) Changes in bone remodeling rate influence the degree of mineralization of bone which is a determinant of bone strength: therapeutic implications. Adv Exp Med Biol 496:123-127
26. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Kaneda K, Minaguchi H, Inoue T, Tomita A, Nagata Y, Nakashima M, Orimo H (1998) A placebo-controlled, single-blind study to determine the appropriate alendronate dosage in postmenopausal Japanese patients with osteoporosis. Endocr J 45:191-201
27. Nakamura T, Kushida K, Shiraki M, Fukunaga M, Taga M, Kishimoto H, Tomita A, Inoue T, Minaguchi H, Kaneda K, Nagata Y, Nakashima M, Orimo H (1998) A double-blind, dose-ranging study of alendronate in patients with involutional osteoporosis, osteoporotic osteopenia or artificial menopause (in Japanese). Med Consul New Remedy 35:3-17
28. Kishimoto H, Shiraki M, Fukunaga M, Kushida K, Kaneda K, Inoue T, Tomita A, Yamamoto K, Orimo H (1998) A long-term study of alendronate in patients with involutional osteoporosis (in Japanese). Med Consul New Remedy 35:19-41
29. Shiraki M, Kushida K, Fukunaga M, Kishimoto H, Taga M, Nakamura T, Kaneda K, Minaguchi H, Inoue T, Morii H, Tomita A, Yamamoto K, Nagata Y, Nakashima M, Orimo H (1999) A double-masked multicenter comparative study between alendronate and alfacalcidol in Japanese patients with osteoporosis. Osteoporos Int 10:183-192
30. de Groen PC, Lubbe DF, Hirsch LJ, Daifotis A, Stephenson W, Freedholm D, Pryor-Tillotson S, Seleznick MJ, Pinkas H, Wang KK (1996) Esophagitis associated with the use of alendronate. N Engl J Med 335:1016-1021
31. Peter CP, Handt LK, Smith SM (1998) Esophageal irritation due to alendronate sodium tablets: possible mechanisms. Dig Dis Sci 43:1998-2002
32. Cryer B, Bauer DC (2002) Oral bisphosphonates and upper gastrointestinal tract problems: what is the evidence? Mayo Clin Proc 77:1031-1043
33. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517-525
34. Miller PD, Woodson G, Licata AA, Ettinger MP, Mako B, Smith ME, Wang L, Yates J, Melton ME, Palmisano JJ (2000) Rechallenge of patients who had discontinued alendronate therapy because of upper gastrointestinal symptoms. Clin Ther 22:1433-1442